| Literature DB >> 33719953 |
Juan J Rodriguez1, Oscar C Munoz2, Mateo Porres-Aguilar3,4, Debabrata Mukherjee5.
Abstract
The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus (SARS- CoV-2) is our latest pandemic and has turned out to be a global public health crisis. One of the special characteristics of this disease is that it may predispose patients to thrombotic disease both in the venous and arterial circulation. We review arterial and venous thromboembolic complications in patients with COVID-19, epidemiology, pathogenesis, hematologic biomarkers, and current antithrombotic strategies. Future perspectives and clinical trials are undergoing to determine best thromboprophylaxis strategies in the hospitalized patients with severe COVID-19. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Entities:
Keywords: Bleeding; COVID-19; Myocardial infarction; Pulmonary embolism; Stroke; Thromboembolism; Thromboprophylaxis; Thrombosis; Venous thromboembolism
Year: 2021 PMID： 33719953 DOI： 10.2174/1871529X21666210315123347
Source DB: PubMed Journal: Cardiovasc Hematol Disord Drug Targets ISSN： 1871-529X